Prolactin‑secreting pituitary tumors, also known as prolactinomas, are endocrine tumors originating from the anterior pituitary gland. Their main characteristic is excessive secretion of prolactin (PRL). The pituitary gland is located in the sella turcica at the base of the brain and is responsible for regulating the secretion of multiple important hormones in the body. Prolactinomas cause elevated blood prolactin levels, leading to a range of clinical symptoms.

Prolactinomas are a relatively complex type of pituitary tumor. They usually present as benign adenomas, meaning that most are non‑invasive and grow slowly. Excessively high prolactin levels have widespread effects on the endocrine system. Typical symptoms include menstrual disorders, infertility, and galactorrhea (lactation outside of breastfeeding) in female patients, while male patients may experience reduced libido, erectile dysfunction, and gynecomastia.

The concept of "cure" for prolactinomas depends on multiple factors, including tumor size, invasiveness, patient response to medication, and the choice of treatment modality. For many cases, particularly microadenomas (less than 1 cm in diameter) and some small invasive adenomas, medical therapy is the preferred option, especially with dopamine receptor agonists. These drugs act on dopamine receptors on pituitary cells to reduce prolactin secretion and may also shrink the tumor, thereby achieving clinical remission. In some patients, long‑term maintenance therapy can even achieve a state akin to "cure."

However, for patients who respond poorly to medical therapy, cannot tolerate side effects, or have large tumors or those that have invaded surrounding structures, surgical treatment may be necessary. Modern neurosurgical techniques, particularly endoscopic endonasal transsphenoidal minimally invasive surgery, allow precise tumor resection under endoscopic guidance, with a relatively high success rate. If the surgery achieves complete tumor removal and no excessive prolactin secretion remains, a cure is theoretically possible. However, due to the variable location of pituitary tumors, total resection is not always feasible, and there is a risk of residual tumor or recurrence.

In addition, for cases where surgery cannot achieve complete resection or is not suitable, radiotherapy is another option, such as stereotactic radiosurgery (e.g., Gamma Knife or CyberKnife) or fractionated stereotactic radiotherapy. CyberKnife, in particular, has shown good results in treating pituitary tumors due to its high precision, allowing targeted delivery of high‑dose radiation to the tumor while maximally protecting surrounding normal tissues.

In summary, although prolactinomas can be effectively controlled and managed to a great extent with the above treatment modalities, a strict "cure" is not always applicable. Even with good control under medical therapy, some patients may experience recurrent elevation of prolactin levels once the medication is discontinued. Therefore, the treatment goals for this disease are more focused on symptom control, restoration of normal hormone levels, prevention of tumor progression, and optimization of quality of life.

The overall treatment strategy for prolactinomas should be individualized, taking into account the patient's specific condition, age, fertility desires, tumor characteristics, and the patient's acceptance of different treatment options. For newly diagnosed small prolactinomas, medical therapy is usually attempted first; if the response is good, regular follow‑up with monitoring of pituitary hormone levels and tumor size is performed.

When medical therapy is ineffective or unsuitable, surgical intervention may be considered. The key to successful surgery lies in finding an experienced neurosurgical team that utilizes advanced techniques and equipment to maximize the chance of total resection and minimize complications.

In cases where there is residual tumor after surgery, or when both medical and surgical treatments are not appropriate, radiotherapy can serve as an adjunctive or alternative therapy to provide further control.

Can prolactin‑secreting pituitary tumors be completely cured?

In conclusion, the treatment of prolactinomas is a multidisciplinary process aimed at balancing therapeutic effects with potential risks, ensuring that the patient's quality of life and endocrine function are restored and protected to the greatest possible extent. Although prolactinomas may not be completely curable in the strict sense, with appropriate treatment and lifestyle adjustments, most patients can achieve good disease control and maintain a satisfactory quality of life. With ongoing advances in medical technology and the development of new drugs, an increasing number of patients can expect better prognoses and improved quality of life.

The above content is for informational purposes only and should not be used as medical advice. For more information about pituitary tumors, please contact us by phone or leave an online message. INC International Neurosurgeons Circle's World Advisory Neurosurgical Group (WANG) includes numerous internationally renowned professors with exceptional technical skills and extensive successful case experience, such as Professor Sebastien Froelich (France), former Chairman of the WFNS Skull Base Surgery Committee, who specializes in endoscopic endonasal skull base tumor resection. His "chopsticks" technique in endoscopic surgery not only improves resection rates but also enhances prognostic outcomes for patients with complex brain tumors such as chordomas, craniopharyngiomas, and pituitary adenomas.

INC (INC) is a physician group focused on academic exchanges among expert professors in the field of neurosurgery. The professors on its various academic teams are members of the World Federation of Neurosurgical Societies (WFNS) and various international neurosurgical academic organizations, editors‑in‑chief of major international neurosurgical journals, and textbook‑level neurosurgical giants who have surgical approaches and anatomical structures named after them in neurosurgery textbooks.